
    
      The investigators designed a prospective phase II study for early-stage NPC patients, and
      proposed a reasonable delineation method of reducing CTV according to the clinical
      characteristics and tumor infiltration patterns, performing therapeutic dose to tumor and
      prophylactic dose to CTV while protecting as much normal tissues as possible, in order to
      ensure a long-term survival with good quality of life.
    
  